Atopic Dermatitis

Should Some Infants be Screened Before Peanut Introduction?
March 23, 2021

An investigation examines which infants might require screening before peanut introduction.

Ruxolitinib Cream NDA Accepted for Priority Review by FDA
March 12, 2021

Incyte announces the FDA has accepted the NDA for ruxolitinib cream for priority review. Ruxolitinib cream is a topical selective janus kinase (JAK)1/JAK2 inhibitor intended for the treatment of atopic dermatitis.

Systemic Therapy Advances for AD
March 10, 2021

The limited armamentarium of systemic therapies for atopic dermatitis has already been expanded with the approval of dupilumab. Forthcoming systemic therapies are expected to include a new biologic and three new Janus kinase (JAK) inhibitors.